First presented by the European Commission way back in 2020, the new pharmaceutical strategy for Europe aimed to make the European pharmaceutical industry, ‘fit for the future and competitive’.

Following the transformative impact of the COVID-19 pandemic, and realisation that there were critical flaws hindering the effective production and roll-out of vital vaccines, a reformed proposal was published in April 2023.

The aim? To strengthen security of supply, promote research and innovation, and improve access to affordable medicinal products.

From ensuring better access to treatments and more reliable, cross-border data sharing, to nurturing the creation of both a well-functioning international supply chain and a well performing single market for pharmaceuticals, no corner of the industry has been left untouched.

The Role of Labelling Compliance in Maintaining the Equilibrium
Accurate and effective labelling permeates all of this, and while it’s often overlooked or perhaps even dismissed as unimportant or not worth investment, the supply chain would – quite literally – grind to a halt without it, hindering access to treatments and cross-border collaboration.

Let me explain.

In an industry where accuracy, safety, and adherence to regulatory standards is paramount, effective labelling isn’t just about clear communication. It’s also about maintaining public trust, meeting legal obligations, and safeguarding patient welfare. Given how quickly global regulatory requirements can change, keeping on top of labelling compliance is becoming an increasing challenge for businesses. Understanding, and navigating, these shifting requirements while also managing a large, diverse product line can feel like an overwhelming task.